Medicaid Rebates Will Get Broad OIG Review After EpiPen

HHS Inspector General tells congressional committee chairmen it will investigate whether other drugs may be improperly classified as generics in Medicaid to avoid higher rebate requirements.

Compliance

More from Pricing Debate

More from Market Access